Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

v3.23.3
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Common Stock
Additional Paid-in- Capital
Treasury Stock
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Total
Beginning balance at Jan. 01, 2022 $ 56 $ 282,663 $ (7,625) $ 274 $ (179,800) $ 95,568
Beginning balance (in shares) at Jan. 01, 2022 52,960          
Increase (Decrease) in Stockholders' Equity            
Net Income (Loss)         2,103 2,103
Issuance of shares in connection with stock option exercise   792       792
Issuance of shares in connection with stock option exercise (in shares) 533          
Issuance of shares in connection with restricted stock units vesting $ 1 (1)        
Issuance of shares in connection with restricted stock units vesting (in shares) 519          
Issuance of stock awards to consultants   81       81
Issuance of stock awards to consultants (in shares) 10          
Issuance of shares in connection with BOD Fees   6       6
Issuance of shares in connection with ESPP   431       431
Issuance of shares in connection with ESPP (in shares) 45          
Officers and directors stock purchase plan   23       23
Officers and directors stock purchase plan (in shares) 3          
Share-based compensation   4,225       4,225
Unrealized gain (loss) on deferred compensation trust assets       (34) (34)
Effect of changes in foreign currencies       20   20
Ending balance at Apr. 02, 2022 $ 57 288,220 (7,625) 260 (177,697) 103,215
Ending balance (in shares) at Apr. 02, 2022 54,070          
Increase (Decrease) in Stockholders' Equity            
Net Income (Loss)         4,118 4,118
Issuance of shares in connection with stock option exercise   136       136
Issuance of shares in connection with stock option exercise (in shares) 70          
Issuance of shares in connection with restricted stock units vesting (in shares) 220          
Issuance of shares in connection with BOD Fees   6       6
Officers and directors stock purchase plan   4       4
Share-based compensation   771       771
Unrealized gain (loss) on deferred compensation trust assets       (100)   (100)
Effect of changes in foreign currencies       104   104
Ending balance at Jul. 02, 2022 $ 57 289,137 (7,625) 264 (173,579) 108,254
Ending balance (in shares) at Jul. 02, 2022 54,360          
Increase (Decrease) in Stockholders' Equity            
Net Income (Loss)         (948) (948)
Issuance of shares in connection with stock option exercise   184       184
Issuance of shares in connection with stock option exercise (in shares) 63          
Issuance of shares in connection with restricted stock units vesting (in shares) 72          
Issuance of shares in connection with BOD Fees   6       6
Issuance of shares in connection with BOD Fees (in shares) 1          
Issuance of shares in connection with ESPP   363       363
Issuance of shares in connection with ESPP (in shares) 62          
Share-based compensation   3,760       3,760
Unrealized gain (loss) on deferred compensation trust assets       (36)   (36)
Ending balance at Oct. 01, 2022 $ 57 293,450 (7,625) 228 (174,527) 111,583
Ending balance (in shares) at Oct. 01, 2022 54,558          
Beginning balance at Dec. 31, 2022 $ 57 297,265 (7,625) 1,126 (180,751) 110,072
Beginning balance (in shares) at Dec. 31, 2022 54,693          
Increase (Decrease) in Stockholders' Equity            
Net Income (Loss)         1,051 1,051
Issuance of shares in connection with stock option exercise $ 1 1,523       1,524
Issuance of shares in connection with stock option exercise (in shares) 972          
Issuance of shares in connection with restricted stock units vesting $ 1         1
Issuance of shares in connection with restricted stock units vesting (in shares) 495          
Issuance of shares in connection with BOD Fees   6       6
Issuance of shares in connection with BOD Fees (in shares) 1          
Issuance of shares in connection with ESPP   221       221
Issuance of shares in connection with ESPP (in shares) 42          
Share-based compensation   4,170       4,170
Unrealized gain (loss) on deferred compensation trust assets       24   24
Ending balance at Apr. 01, 2023 $ 59 303,185 (7,625) 1,150 (179,700) 117,069
Ending balance (in shares) at Apr. 01, 2023 56,203          
Beginning balance at Dec. 31, 2022 $ 57 297,265 (7,625) 1,126 (180,751) $ 110,072
Beginning balance (in shares) at Dec. 31, 2022 54,693          
Increase (Decrease) in Stockholders' Equity            
Issuance of shares in connection with stock option exercise (in shares)           1,655
Ending balance at Sep. 30, 2023 $ 60 309,106 (9,766) 1,153 (182,888) $ 117,665
Ending balance (in shares) at Sep. 30, 2023 57,497          
Beginning balance at Apr. 01, 2023 $ 59 303,185 (7,625) 1,150 (179,700) 117,069
Beginning balance (in shares) at Apr. 01, 2023 56,203          
Increase (Decrease) in Stockholders' Equity            
Net Income (Loss)         (671) (671)
Issuance of shares in connection with stock option exercise   446       446
Issuance of shares in connection with stock option exercise (in shares) 279          
Issuance of shares in connection with restricted stock units vesting (in shares) 431          
Issuance of shares in connection with BOD Fees   5       5
Issuance of shares in connection with BOD Fees (in shares) 1          
Share-based compensation   2,937       2,937
Stock repurchase   (5) (1,047)     (1,052)
Unrealized gain (loss) on deferred compensation trust assets       24   24
Ending balance at Jul. 01, 2023 $ 59 306,568 (8,672) 1,174 (180,371) 118,758
Ending balance (in shares) at Jul. 01, 2023 56,914          
Increase (Decrease) in Stockholders' Equity            
Net Income (Loss)         (2,517) (2,517)
Issuance of shares in connection with stock option exercise $ 1 635       636
Issuance of shares in connection with stock option exercise (in shares) 404          
Issuance of shares in connection with restricted stock units vesting (in shares) 105          
Issuance of shares in connection with BOD Fees   6       6
Issuance of shares in connection with BOD Fees (in shares) 1          
Issuance of shares in connection with ESPP   262       262
Issuance of shares in connection with ESPP (in shares) 73          
Share-based compensation   1,640       1,640
Stock repurchase   (5) (1,094)     (1,099)
Unrealized gain (loss) on deferred compensation trust assets       (21)   (21)
Ending balance at Sep. 30, 2023 $ 60 $ 309,106 $ (9,766) $ 1,153 $ (182,888) $ 117,665
Ending balance (in shares) at Sep. 30, 2023 57,497